Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Is it possible to reach an operational cure for CML?

Giuseppe Saglio • 9 Jun 2016
EHA 2016
Chronic Myeloid Leukemia

Giuseppe Saglio, MD from University of Turin, Turin, Italy discusses the influence of tyrosine kinase inhibitor (TKI) therapy on the treatment of chronic myeloid leukemia (CML). Over the past few years it has been shown that patients can achieve a status called operational cure, where it is possible for them to stop therapy – however, the number of patients holding this status is low. Prof Saglio holds hope that in the future this number will rise and mentions the potential of using a stronger TK inhibitor to increase the number of patients holding an operational cure. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark

More from Giuseppe Saglio

2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
Giuseppe Saglio • 25 Oct 2022
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
2:11
Addressing the issue of resistance to TKIs in CML
Giuseppe Saglio • 28 Oct 2022
3:35
TKI-related toxicities in CML & the importance of long-term monitoring
Giuseppe Saglio • 28 Sep 2022

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:02
Optimizing myeloablative conditioning with precision-engineered Orca-T in older patients
Caspian Oliai • 10 Dec 2023
3:21
A Phase I trial of Hu8F4, an anti-PR1/HLA-A2 monoclonal antibody, in R/R myeloid malignancies
Tapan Kadia • 14 Dec 2023
6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
The content of VJHemOnc is intended for healthcare professionals